%D9%88%D8%B1%D8%A7%D9%85_%D8%AD%D8%A8%D9%8A%D8%A8%D9%8A_%D9%88%D9%8A%D8%BA%D9%86%D8%B1%D9%8ACategory:Wegener%27s_granulomatosisGranulomatose_mit_Polyangiitis%CE%91%CE%B3%CE%B3%CE%B5%CE%B9%CE%AF%CF%84%CE%B9%CE%B4%CE%B1_WegenerGranulomatosis_with_polyangiitisGranulomatosis_con_poliangitis%DA%AF%D8%B1%D8%A7%D9%86%D9%88%D9%84%D9%88%D9%85%D8%A7%D8%AA%D9%88%D8%B2_%D9%88%DA%AF%D9%86%D8%B1Wegenerin_granulomatoosiGranulomatose_avec_polyang%C3%A9ite%D7%9E%D7%97%D7%9C%D7%AA_%D7%95%D7%92%D7%A0%D7%A8%D4%B3%D6%80%D5%A1%D5%B6%D5%B8%D6%82%D5%AC%D5%A5%D5%B4%D5%A1%D5%BF%D5%B8%D5%A6_%D5%BA%D5%B8%D5%AC%D5%AB%D5%A1%D5%B6%D5%A3%D5%AB%D5%AB%D5%BF%D5%B8%D5%BEGranulomatosis_WegenerGranulomatosi_associata_a_poliangioite%E5%A4%9A%E7%99%BA%E8%A1%80%E7%AE%A1%E7%82%8E%E6%80%A7%E8%82%89%E8%8A%BD%E8%85%AB%E7%97%87%EB%8B%A4%EB%B0%9C%EC%84%B1_%EB%A7%A5%EA%B4%80%EC%97%BC_%EB%8F%99%EB%B0%98_%EC%9C%A1%EC%95%84%EC%A2%85Granulomatose_de_Wegener%D0%92%D0%B5%D0%B3%D0%B5%D0%BD%D0%B5%D1%80%D0%BE%D0%B2%D0%B0_%D0%B3%D1%80%D0%B0%D0%BD%D1%83%D0%BB%D0%BE%D0%BC%D0%B0%D1%82%D0%BE%D0%B7%D0%B0Granulomatose_met_polyangiitisGranulomatose_med_polyangiittZiarniniakowato%C5%9B%C4%87_z_zapaleniem_naczy%C5%84Granulomatose_com_poliangiite%D0%93%D1%80%D0%B0%D0%BD%D1%83%D0%BB%D0%B5%D0%BC%D0%B0%D1%82%D0%BE%D0%B7_%D0%92%D0%B5%D0%B3%D0%B5%D0%BD%D0%B5%D1%80%D0%B0Granulomat%C3%B6s_polyangitWegener_gran%C3%BClomatozu%D0%A1%D0%B8%D0%BD%D0%B4%D1%80%D0%BE%D0%BC_%D0%92%D0%B5%D0%B3%D0%B5%D0%BD%D0%B5%D1%80%D0%B0Q1161568%E8%82%89%E8%8A%BD%E8%85%AB%E4%BD%B5%E5%A4%9A%E7%99%BC%E6%80%A7%E8%A1%80%E7%AE%A1%E7%82%8E
about
Cindy AbbottAmerican College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic VasculitisSafety and Efficacy Study of IFX-1 in add-on to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic PolyangiitisMycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)Low Dose Naltrexone to Improve Physical Health in Patients With VasculitisClinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's GranulomatosisOne-Time DNA Study for VasculitisJourney of Patients With Vasculitis From First Symptom to DiagnosisYellow Fever Vaccine in Patients With Rheumatic DiseasesStudy of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)Cardiovascular Involvement in Patients With Granulomatosis With PolyangiitisPlasma Exchange for Renal VasculitisAlemtuzumab for ANCA Associated Refractory VasculitisStudy of One Protein Implicated in Wegener DiseaseBelimumab in Remission of VASculitisA Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic PolyangiitisAn Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic PolyangiitisRituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up StudyA Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic PolyangitisPlasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis (PEXIVAS) - GlucocorticoidsEvaluation of Novel Lung Function Parameters in Patients With Interstitial Lung Disease (ILD)Vasculitis Pregnancy RegistryTEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With PolyangiitisClinical Transcriptomics in Systemic Vasculitis (CUTIS)A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With PolyangiitisPediatric Vasculitis InitiativeInduction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory DiseasesVCRC Patient Contact Registry Patient-Reported Data Validation StudyEducational Needs of Patients With Systemic VasculitisVasculitis Illness Perception (VIP) StudyLow-dose Glucocorticoid Vasculitis Induction StudyReproductive Health in Men and Women With VasculitisComparison Study of Two Rituximab Regimens in the Remission of ANCA Associated VasculitisPRO Development for ANCA Associated VasculitisRituximab Vasculitis Maintenance StudyBIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel VasculitisPlasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated VasculitisAnti-Cytokine Therapy for Vasculitis
P1050
P5132
Wegener's granulomatosis: current and upcoming therapiesStaphylococcus aureus and Wegener's granulomatosis.Eosinophilic Granulomatosis With Polyangiitis With Thrombotic Microangiopathy: Is Simultaneous Systemic Lupus Erythematosus Associated With Clinical Manifestations?: A Case Report and Review of the LiteratureGranulomatose avec polyangéite du sujet âgé: à propos de deux cas et revue de la littératureInterleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needsChildhood-onset granulomatosis with polyangiitis and microscopic polyangiitis: systematic review and meta-analysisLung involvement in childhood onset granulomatosis with polyangiitis.Antineutrophil cytoplasmic antibody positivity in IgG4-related disease: A case report and review of the literatureProgressive dyspnoea following the treatment of Mycobacterium abscessus infection in an individual with relapsing granulamatosis with polyangitis (Wegener's), complicated by hearing loss requiring cochlear implantationCurrent therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximabAccessory left gastric artery aneurysms in granulomatosis with polyangiitis: a case report and literature review.Pituitary dysfunction in granulomatosis with polyangiitis.Pulmonary renal syndromes. II. Etiology and pathogenesis.Heart conduction system defects and sustained ventricular tachycardia complications in a patient with granulomatosis with polyangiitis. A case report and literature review.Risk factors and treatment of pneumothorax secondary to granulomatosis with polyangiitis: a clinical analysis of 25 cases.Methylprednisolone and plasmapheresis are effective for life-threatening diffuse alveolar hemorrhage and gastrointestinal hemorrhage in granulomatosis with polyangiitis: A case report and literature review.Severe localised granulomatosis with polyangiitis (Wegener's granulomatosis) manifesting with extensive cranial nerve palsies and cranial diabetes insipidus: a case report and literature review.Co-Presentation of Giant Cell Arteritis and Granulomatosis with Polyangiitis: A Case Report and Review of Literature.Death of Wegener.Severe ophthalmic manifestation in pituitary-involved granulomatosis with polyangiitis: a case report and literature reviewA rare case report of polyangiitis overlap syndrome: granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitisDevelopment of CT-based methods for longitudinal analyses of paranasal sinus osteitis in granulomatosis with polyangiitisIgG4:IgG RNA ratio differentiates active disease from remission in granulomatosis with polyangiitis: a new disease activity marker? A cross-sectional and longitudinal studyOne-Time DNA Study for VasculitisAbatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated VasculitisTemporal and Cartographic Analyses of the Distribution within Spain of Mortality Due to Granulomatosis with Polyangiitis (1984⁻2016)Head and Neck Manifestations of Granulomatosis with Polyangiitis: A Retrospective analysis of 19 Patients and Review of the Literature18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Assessment of Occult Involvement in Widespread Granulomatosis with Polyangiitis (Wegener's Granulomatosis)Eosinophils in anti-neutrophil cytoplasmic antibody associated vasculitisLumps and Bumps of the Gingiva: A Pathological MiscellanyMolecular targeted therapies for microscopic polyangiitis and granulomatosis with polyangiitis
P921
Q18643310-554764d7-4dcf-5989-8c62-92836d21d86fQ61939284-4123A4A5-2AB6-4437-8486-42455F9A0CA6Q62041682-3BFC00C2-7B82-443A-97E6-E22EACD7BD34Q62105887-DF4E648B-EC20-44CF-8D37-B2A1BCD80CFFQ62105931-10098AA3-BD34-4FC4-A44C-7121D760F703Q62810428-FDE30138-9BE4-467E-B10E-4BD8A56CCFB2Q63321564-6CD4A838-0C2D-4025-A349-F430A363D93EQ63340223-5D4D9D89-BA16-4C71-A07C-05CBE1AF93B4Q63402938-F3FC7DAB-4910-4CD1-B68F-62D6A8C0B573Q63404284-A6B9C89C-539E-436A-8C50-760F8DEA2DBFQ63580446-A48E5234-842B-40F1-8798-C0C108F03EDDQ63590740-A3D183F7-CE63-42BD-ACC3-7933D49886FDQ63593070-DF9A16E5-579B-4E2B-9687-FB9A77FDC979Q63806585-F38B0018-7800-4299-B5A8-67809794FEDFQ63806847-8EE2ADD6-07BE-4DCA-8728-79B8CA9C72F8Q63832587-224CDECA-E424-4B1C-A65E-FDDE4E2B7054Q63838526-4ABA92C7-CB71-4118-A5DE-40A3F7199523Q63840612-2380555D-83D8-454F-A628-F8BFADB21F01Q63843424-4ADD0321-B131-4235-A4E6-124E442A230FQ63844398-85F92C5C-289F-4C62-8492-ED9928059960Q64140221-B299421F-08B2-41C5-B12F-C91FF1E0C499Q64172206-946EE315-2776-4D2A-80B0-FCD9C0081178Q64173158-A20C3538-D934-4EA2-9958-302F9C5F903BQ64183710-B5F491E0-F988-478B-B2FD-D925A288F299Q64183858-C46483D4-D5DD-45BD-83FC-6BB6698EAB85Q64189818-5D001193-C37E-4A55-B1DE-3301F0D676DAQ64350313-8920DA3F-9BAA-4BE9-83AF-0498E8279820Q64351519-D4C5CA70-B642-454C-90AC-630BD96943DFQ64351874-2A04885C-5470-4CE8-8282-9B359EAF764BQ64607539-6CF65419-038D-475A-B41B-7E29117F04A2Q64607540-26219B1C-8E64-48A9-8132-A8A66A8F68FDQ64607541-FB2F7BCF-49B2-41D5-97A2-CF6C7C7B0EB4Q64609883-59D4E12E-70E4-4A84-A4D9-BCE81FB5BA0CQ64611317-7B9710E3-F2CC-4D8C-8FCE-BDC63A97D7FDQ64637682-1D9E24F7-3383-46B2-955F-33DBBC7E3E25Q64638046-2912DE06-57D0-4ABA-8CC7-D1F17840DD30Q64639991-07C02F24-D301-4E19-8D84-5DB1182978FFQ64645377-5DE9273E-29A0-4922-A1C5-14F0039E37E5Q64662045-52B54A18-27D9-41C6-93BE-09CCD6C0531AQ64716321-20CB8741-EE8B-40D1-968C-47A53454EDC6
P1050
description
Krankheit
@de
autoimmune disease affecting blood vessels in the lungs, kidneys, and skin
@en
malattia dell'apparato respiratorio
@it
systémové onemocnění pojivové tkáně
@cs
گرانولوماتوز همراه با پلیآنژیت
@fa
name
Granulomatose de Wegener
@fr
Granulomatose de Wegener
@lfn
Granulomatose de Wegener
@pt
Granulomatose med polyangiitt
@nb
Granulomatosis Wegener
@id
Granulomatosis con poliangitis
@es
Wegener granülomatozu
@tr
Wegener-Granulomatose
@de
Wegenerin granulomatoosi
@fi
Wegenerova granulomatóza
@cs
type
label
Granulomatose de Wegener
@fr
Granulomatose de Wegener
@lfn
Granulomatose de Wegener
@pt
Granulomatose med polyangiitt
@nb
Granulomatosis Wegener
@id
Granulomatosis con poliangitis
@es
Wegener granülomatozu
@tr
Wegener-Granulomatose
@de
Wegenerin granulomatoosi
@fi
Wegenerova granulomatóza
@cs
altLabel
ANCA-associated vasculitis
@en
GPA
@en
Granulomatose van Wegener
@nl
Granulomatosis - Wegener's
@en
Granulomatosis With Polyangiitis
@en
Granulomatosis de la mediana edad
@es
Granulomatosis with polyangiitis; GPA
@en
Granulomatosis with polyangiits; GPA
@en
Granulomatöse Polyangiitis
@de
Klinger-Wegeners syndrom
@sv
prefLabel
Granulomatose de Wegener
@fr
Granulomatose de Wegener
@lfn
Granulomatose de Wegener
@pt
Granulomatose med polyangiitt
@nb
Granulomatosis Wegener
@id
Granulomatosis con poliangitis
@es
Wegener granülomatozu
@tr
Wegener-Granulomatose
@de
Wegenerin granulomatoosi
@fi
Wegenerova granulomatóza
@cs
P1748
P279
P2888
P2892
P672
P486
P646
P1325
P1417
science/Wegener-granulomatosis
P1461
Granulomatosis with polyangiitis